Human Hepatic Stellate Cells: Isolation and Characterization.
Enzymatic digestion
Gradient centrifugation
Human hepatic stellate cells
Liver fibrosis
Myofibroblasts
Whole human livers
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
31
5
2023
pubmed:
29
5
2023
entrez:
29
5
2023
Statut:
ppublish
Résumé
Liver fibrosis of different etiologies is characterized by activation of hepatic stellate cells (aHSCs) into collagen type I secreting myofibroblasts, which produce fibrous scar and make the liver fibrotic. aHSCs are the major source of myofibroblasts and, therefore, the primary targets of anti-fibrotic therapy. Despite extensive studies, targeting of aHSCs in patients provides challenges. The progress in anti-fibrotic drug development relies on translational studies but is limited by the availability of primary human HSCs. Here we describe a perfusion/gradient centrifugation-based method of the large-scale isolation of highly purified and viable human HSCs (hHSCs) from normal and diseased human livers and the strategies of hHSC cryopreservation.
Identifiants
pubmed: 37247063
doi: 10.1007/978-1-0716-3207-9_13
doi:
Substances chimiques
Collagen Type I
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
221-232Informations de copyright
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Loomba R, Sanyal AJ (2013) The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10:686–690
doi: 10.1038/nrgastro.2013.171
pubmed: 24042449
Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ (2018) Mechanisms of NAFLD development and therapeutic strategies. Nat Med 24:908–922
doi: 10.1038/s41591-018-0104-9
pubmed: 29967350
pmcid: 6553468
Kisseleva T, Brenner D (2021) Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol 18:151–166
doi: 10.1038/s41575-020-00372-7
pubmed: 33128017
Kendall TJ et al (2009) p75 Neurotrophin receptor signaling regulates hepatic myofibroblast proliferation and apoptosis in recovery from rodent liver fibrosis. Hepatology 49:901–910
doi: 10.1002/hep.22701
pubmed: 19072833
Sachs BD et al (2007) p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway. J Cell Biol 177:1119–1132
doi: 10.1083/jcb.200701040
pubmed: 17576803
pmcid: 2064370
Friedman SL, Roll FJ, Boyles J, Bissell DM (1985) Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci USA 82:8681–8685
doi: 10.1073/pnas.82.24.8681
pubmed: 3909149
pmcid: 391500
Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115:209–218
doi: 10.1172/JCI24282
pubmed: 15690074
pmcid: 546435
Naugler WE et al (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317:121–124
doi: 10.1126/science.1140485
pubmed: 17615358
Gu FM et al (2011) IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. Mol Cancer 10:150
doi: 10.1186/1476-4598-10-150
pubmed: 22171994
pmcid: 3310750
Li J et al (2011) Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PLoS One 6:e21816
doi: 10.1371/journal.pone.0021816
pubmed: 21760911
pmcid: 3131399
Di Rosa M, Malaguarnera L (2012) Genetic variants in candidate genes influencing NAFLD progression. J Mol Med (Berl) 90:105–118
doi: 10.1007/s00109-011-0803-x
pubmed: 21894552
Generon (Shanghai) Corporation Ltd (2012) Generon initiates a phase I clinical study for F-652 in Australia. Business Wire, A Berkshire Hathaway
Ichikawa S, Mucida D, Tyznik AJ, Kronenberg M, Cheroutre H (2011) Hepatic stellate cells function as regulatory bystanders. J Immunol 186:5549–5555
doi: 10.4049/jimmunol.1003917
pubmed: 21460203
Saito Y, Morine Y, Shimada M (2017) Mechanism of impairment on liver regeneration in elderly patients: role of hepatic stellate cell function. Hepatol Res 47:505–513
doi: 10.1111/hepr.12872
pubmed: 28186674
Lee JS, Semela D, Iredale J, Shah VH (2007) Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte? Hepatology 45:817–825
doi: 10.1002/hep.21564
pubmed: 17326208
Hernandez-Gea V, Friedman SL (2011) Pathogenesis of liver fibrosis. Annu Rev Pathol 6:425–456
doi: 10.1146/annurev-pathol-011110-130246
pubmed: 21073339
Shang L, Hosseini M, Liu X, Kisseleva T, Brenner DA (2018) Human hepatic stellate cell isolation and characterization. J Gastroenterol 53:6–17
doi: 10.1007/s00535-017-1404-4
pubmed: 29094206
Knook DL, Seffelaar AM, de Leeuw AM (1982) Fat-storing cells of the rat liver. Their isolation and purification. Exp Cell Res 139:468–471
doi: 10.1016/0014-4827(82)90283-X
pubmed: 7084333
Mederacke I, Dapito DH, Affo S, Uchinami H, Schwabe RF (2015) High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers. Nat Protoc 10:305–315
doi: 10.1038/nprot.2015.017
pubmed: 25612230
pmcid: 4681437
Xu L et al (2005) Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54:142–151
doi: 10.1136/gut.2004.042127
pubmed: 15591520
pmcid: 1774377
Schnabl B, Purbeck CA, Choi YH, Hagedorn CH, Brenner D (2003) Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology 37:653–664
doi: 10.1053/jhep.2003.50097
pubmed: 12601363
Herrmann J, Gressner AM, Weiskirchen R (2007) Immortal hepatic stellate cell lines: useful tools to study hepatic stellate cell biology and function? J Cell Mol Med 11:704–722
doi: 10.1111/j.1582-4934.2007.00060.x
pubmed: 17760834
pmcid: 3823251
Coll M et al (2018) Generation of hepatic stellate cells from human pluripotent stem cells enables in vitro modeling of liver fibrosis. Cell Stem Cell 23(101–113):e107
Baeza-Raja B et al (2020) Pharmacological inhibition of P2RX7 ameliorates liver injury by reducing inflammation and fibrosis. PLoS One 15:e0234038
doi: 10.1371/journal.pone.0234038
pubmed: 32492075
pmcid: 7269334
Chinnadurai R et al (2019) Molecular genetic and immune functional responses distinguish bone marrow mesenchymal stromal cells from hepatic stellate cells. Stem Cells 37:1075–1082
doi: 10.1002/stem.3028
pubmed: 31033095
Liu X et al (2020) Primary alcohol-activated human and mouse hepatic stellate cells share similarities in gene-expression profiles. Hepatol Commun 4:606–626
doi: 10.1002/hep4.1483
pubmed: 32258954
pmcid: 7109347
Liu X et al (2020) Identification of lineage-specific transcription factors that prevent activation of hepatic stellate cells and promote fibrosis resolution. Gastroenterology 158(6):1728–1744.e14
Povero D et al (2019) Human induced pluripotent stem cell-derived extracellular vesicles reduce hepatic stellate cell activation and liver fibrosis. JCI Insight 5(14):e125652
doi: 10.1172/jci.insight.125652
pubmed: 31184999
Drinane MC et al (2017) Synectin promotes fibrogenesis by regulating PDGFR isoforms through distinct mechanisms. JCI Insight 2(24):e92821
doi: 10.1172/jci.insight.92821
pubmed: 29263300
pmcid: 5752303
Xu J et al (2017) The role of human cytochrome P450 2E1 in liver inflammation and fibrosis. Hepatol Commun 1:1043–1057
doi: 10.1002/hep4.1115
pubmed: 29404441
pmcid: 5721400
Baglieri J, Brenner DA, Kisseleva T (2019) The role of fibrosis and liver-associated fibroblasts in the pathogenesis of hepatocellular carcinoma. Int J Mol Sci 20(7):1723
doi: 10.3390/ijms20071723
pubmed: 30959975
pmcid: 6479943
Rady B et al (2021) PNPLA3 downregulation exacerbates the fibrotic response in human hepatic stellate cells. PLoS One 16:e0260721
doi: 10.1371/journal.pone.0260721
pubmed: 34879108
pmcid: 8654208
Kegel V et al (2016) Protocol for isolation of primary human hepatocytes and corresponding major populations of non-parenchymal liver cells. J Vis Exp 109:e53069
Kleiner DE et al (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313–1321
doi: 10.1002/hep.20701
pubmed: 15915461
Romeo S et al (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40:1461–1465
doi: 10.1038/ng.257
pubmed: 18820647
pmcid: 2597056
Seki E et al (2007) TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 13:1324–1332
doi: 10.1038/nm1663
pubmed: 17952090